Progetti FP7 coordinati da "Erasmus universitair medisch centrum rotterdam"
| # | ||||
|---|---|---|---|---|
| 1 | EU-ADR Exploring and understanding adverse drug reactions by integrative mining of clinical records and biomedical knowledge | 2008 | 5˙871˙496.00 | 4˙500˙000.00 |
| 2 | GENETICS OF TIMING A Genetics Approach to the Interval Timing Mechanism | 2008 | 75˙000.00 | 75˙000.00 |
| 3 | IVANG Development of a model of in vitro endochondral ossification with neovascularisation | 2008 | 119˙575.00 | 119˙575.00 |
| 4 | GEFOS GENETIC FACTORS FOR OSTEOPOROSIS | 2008 | 4˙648˙972.00 | 2˙998˙650.00 |
| 5 | NGIDD Neuron-Glia Interactions in Nerve Development and Disease | 2008 | 3˙887˙956.00 | 3˙000˙000.00 |
| 6 | LMOFUNDYN Function and dynamics of Lmo4-containing complexes during erythropoiesis | 2008 | 165˙996.00 | 165˙996.00 |
| 7 | DYNASING Dynamic single-molecule approach to DNA homologous recombination | 2008 | 226˙806.00 | 226˙806.00 |
| 8 | NANO-PHOTOMED Targeted Nano-Photomedicines for Multi-spectral Photodynamic Therapy of Cancer | 2008 | 83˙848.00 | 83˙848.00 |
| 9 | MOODINFLAME "Early diagnosis, treatment and prevention of mood disorders targetting the activated inflammatory response system" | 2008 | 13˙761˙545.00 | 10˙235˙585.00 |
| 10 | SOS Safety Of non-Steroidal anti-inflammatory drugs | 2008 | 3˙767˙705.00 | 2˙800˙000.00 |
| 11 | EMPERIE European Management Platform for Emerging and Re-emerging Infectious disease Entities | 2009 | 15˙967˙125.00 | 11˙909˙560.00 |
| 12 | ELANSCI Role of Lgi and Adam proteins in nerve development and function | 2009 | 161˙162.00 | 161˙162.00 |
| 13 | PRO-NEST Prostate Research Organizations-Network of Early Stage Training | 2009 | 5˙179˙226.00 | 5˙179˙226.00 |
| 14 | ARITMO Arrhythmogenic potential of drugs | 2010 | 3˙616˙797.00 | 2˙748˙319.00 |
| 15 | DAMAGE "DNA damage and the connection with cancer, premature aging and longevity" | 2010 | 2˙000˙000.00 | 2˙000˙000.00 |
| 16 | DNA-DAMAGE REDOX AGE Synergistic effect of DNA damage and oxidative stress in aging | 2010 | 100˙000.00 | 100˙000.00 |
| 17 | TEMPOTEST-QC An Integrated Tool-Kit for the Clinical Evaluation of Microbial Detection and Antibiotic Susceptibility Point-of-Care Testing Technologies | 2010 | 4˙111˙659.00 | 3˙064˙462.00 |
| 18 | LIVING DONATION Living Organ Donation in Europe | 2010 | 1˙250˙335.00 | 1˙099˙657.00 |
| 19 | FLUPLAN Novel strategies to combat future influenza pandemics | 2010 | 2˙187˙758.00 | 2˙187˙758.00 |
| 20 | OXIDNA-REPAIR-CHROMA Unraveling the role of Nucleotide Excision Repair factors and the dynamic of chromatin structure in the repair of oxidative DNA damages in vivo | 2010 | 168˙035.00 | 168˙035.00 |
| 21 | MMSR The Molecular Mechanisms of Stem Cell Self Renewal | 2010 | 100˙000.00 | 100˙000.00 |
| 22 | VECTORIE Vector-borne Risks for Europe: Risk assessment and control of West Nile and Chikungunya virus (VECTORIE) | 2010 | 3˙791˙100.00 | 2˙784˙402.00 |
| 23 | MAPPING FEAR MEMORY Identification and selective targeting of neuronal networks underlying memory | 2011 | 169˙535.00 | 169˙535.00 |
| 24 | DDRESPONSE The DNA damage response and breast cancer | 2011 | 8˙165˙981.00 | 6˙000˙000.00 |
| 25 | DNAREPAIR AT 3DETAIL Recombinational DNA repair analyzed by simultaneous scanning force and single molecule fluorescence microscopy: role of RAD54 in presynaptic and postsynaptic events | 2011 | 45˙000.00 | 45˙000.00 |
| 26 | ACTIVATION OF XCI Molecular mechanisms controlling X chromosome inactivation | 2011 | 1˙500˙000.00 | 1˙500˙000.00 |
| 27 | SAFEGUARD Safety Evaluation of Adverse Reactions in Diabetes | 2011 | 3˙881˙341.00 | 2˙997˙196.00 |
| 28 | ANTIGONE ANTIcipating the Global Onset of Novel Epidemics | 2011 | 15˙686˙261.00 | 11˙997˙709.00 |
| 29 | AIDA Preserving old antibiotics for the future : assessment of clinical efficacy by a pharmacokinetic/pharmacodynamic approach to optimize effectiveness and reduce resistance for off-patent antibiotics | 2011 | 7˙768˙104.00 | 5˙999˙860.00 |
| 30 | PARCIVAL Partner Network for a Clinically Validated Multi-Analyte Lab-on-a-Chip Platform | 2012 | 4˙132˙600.00 | 2˙973˙550.00 |
| 31 | DEMETRIQ Developing methodologies to reduce inequalities in the determinants of health | 2012 | 3˙930˙529.00 | 3˙000˙000.00 |
| 32 | E-COM@EU Effective Communication in Outbreak Management: development of an evidence-based tool for Europe | 2012 | 2˙620˙373.00 | 1˙999˙607.00 |
| 33 | A20 DC SUBSETS Immune regulation of NF-kappaB in Dendritic Cell subsets by the ubiquitin editing enzyme A20 | 2012 | 100˙000.00 | 100˙000.00 |
| 34 | CCC Cracking the Cerebellar Code | 2012 | 2˙499˙600.00 | 2˙499˙600.00 |
| 35 | PSYCH-AID Advanced Immuno-neuro-endocrine Diagnostics in Psychiatry | 2012 | 3˙649˙514.00 | 3˙649˙514.00 |
| 36 | SAVING DYING NEURONS Immune responses in neurodegenerative diseases: Protection or progression? | 2012 | 100˙000.00 | 100˙000.00 |
| 37 | INFLUENZA TROPISM Evolutionary Determinants of Influenza Virus Pathogenesis and Tissue Tropism | 2012 | 183˙805.00 | 183˙805.00 |
| 38 | ROBINSCA "New and more individualised population-based screening for cardiovascular disease; from a RCT including selfassessments, primary care and coronary artery calcification score to modelling risk-benefit" | 2012 | 3˙298˙999.00 | 3˙298˙999.00 |
| 39 | ARCAS ARCAS: Analysis of the Route to Commercialisation of MVA based influenza vaccines | 2012 | 164˙400.00 | 149˙840.00 |
| 40 | LCLT LED Cued Learning Technology | 2013 | 168˙223.00 | 149˙999.00 |
| 41 | TRIPLE-BC Identification and functional validation of drugable targets/pathways for triple negative breast cancer | 2013 | 2˙495˙101.00 | 2˙495˙101.00 |
| 42 | BIOCCORA Full biomechanical characterization of the coronary atherosclerotic plaque: biomechanics meets imaging | 2013 | 1˙877˙000.00 | 1˙877˙000.00 |
| 43 | NABARSI New AntiBacterials with Inhibitory activity on Aminoacyl-tRNA Synthetases | 2013 | 5˙389˙151.00 | 4˙102˙157.00 |
| 44 | TAILORED-TREATMENT DEVELOPMENT OF TAILORED ANTIMICROBIAL TREATMENT REGIMENS AND NOVEL HOST- PATHOGEN INSIGHTS FOR RESPIRATORY TRACT INFECTIONS AND SEPSIS | 2013 | 7˙767˙671.00 | 5˙975˙383.00 |
| 45 | FLUNIVAC InFLUenza virus UNIVersal VACcine development program | 2013 | 6˙973˙633.00 | 5˙066˙881.00 |
| 46 | ASKLEPIOS Advanced Studies towards Knowledge on Lyssavirus Encephalitis Pathogenesis Improving Options for Survival | 2013 | 4˙072˙356.00 | 2˙994˙881.00 |
| 47 | ACTION Advance Care Planning; an Innovative Palliative Care Intervention to Improve Quality of Life in Cancer Patients - a Multi-Centre Cluster Randomized Clinical Trial | 2013 | 6˙122˙871.00 | 4˙784˙656.00 |
| 48 | ERC-ID Excision Repair and chromatin interaction dynamics | 2014 | 2˙500˙000.00 | 2˙500˙000.00 |
| 49 | TRXN-PURGE Mechanisms of transcription in HIV latency; novel strategies to activate | 2014 | 1˙499˙942.00 | 1˙499˙942.00 |
| 50 | WILD SCOPE Early detection of emerging viruses by next generation in situ hybridization | 2014 | 175˙974.00 | 175˙974.00 |
| 51 | ID PHYSIOLOGY Do individuals with intellectual disabilities have an abnormal physiological response to exercise? | 2015 | 173˙640.00 | 173˙640.00 |
Altri progetti
L'Ente erasmus universitair medisch centrum rotterdam partecipato anche in questi progetti.
- ADITEC (2011, participant)
- CHANCES (2010, participant)
- CEREBRAD (2011, participant)
- COMMHERE (2011, participant)
- STROMA (2012, participant)
- CALLISTO (2012, participant)
- EURHEALTHAGEING (2012, participant)
- OCTIPS (2012, participant)
- BIOMEDBRIDGES (2012, participant)
- EARLYNUTRITION (2012, participant)
- REPRO-TRAIN (2012, participant)
- EUROFORGEN-NOE (2012, participant)
- REGENER-AR (2012, participant)
- CCC (2012, hostInstitution)
- CCC (2012, hostInstitution)
- EUCLIDS (2011, participant)
- INTERBONE (2012, participant)
- MANTRA (2012, participant)
- PATHSEEK (2012, participant)
- BIOPOOL (2012, participant)
- TRACENTREAT (2012, participant)
- NEUROKINE (2013, participant)
- ADDRESS (2012, participant)
- D-BOARD (2012, participant)
- COMBI-BIO (2012, participant)
- MARRIAGE (2012, participant)
- ARCAS (2012, hostInstitution)
- ROBINSCA (2012, hostInstitution)
- ROBINSCA (2012, hostInstitution)
- IMPROVED (2012, participant)
- MEUSIX (2012, participant)
- COBRA (2013, participant)
- THALAMOSS (2012, participant)
- RAIDS (2012, participant)
- ATTACK (2012, participant)
- LCLT (2013, hostInstitution)
- BIOCCORA (2013, hostInstitution)
- BIOCCORA (2013, hostInstitution)
- TRIPLE-BC (2013, hostInstitution)
- TRIPLE-BC (2013, hostInstitution)
- VPH-DARE@IT (2013, participant)
- PANCARELIFE (2013, participant)
- EARIP (2013, participant)
- MERLIN (2014, participant)
- CLOSED (2013, participant)
- CAREMORE (2013, participant)
- CENTER-TBI (2013, participant)
- LENA (2013, participant)
- EEC (2013, participant)
- PREPARE (2014, participant)
- MILESTONE (2014, participant)
- BIO-INSPIRE (2013, participant)
- IHIVARNA (2013, participant)
- GAPP (2013, participant)
- SICTEC (2013, participant)
- PNEUMONP (2014, participant)
- ERC-ID (2014, hostInstitution)
- ERC-ID (2014, hostInstitution)
- TRXN-PURGE (2014, hostInstitution)
- TRXN-PURGE (2014, hostInstitution)
- ACTION (2014, participant)
- SEMCARE (2014, participant)
- BREAST CT (2008, participant)
- ELIXIR (2007, participant)
- TUMIC (2008, participant)
- EUCLYD (2008, participant)
- AHEAD III (2008, participant)
- GEN2PHEN (2008, participant)
- UEPHA-MS (2008, participant)
- OPCARE9 (2008, participant)
- TREAT OA (2008, participant)
- MARK-AGE (2008, participant)
- ENGAGE (2008, participant)
- PROSPER (2008, participant)
- EURODSD (2008, participant)
- INTEGRIS (2008, participant)
- UROMOL (2008, participant)
- ATHEROREMO (2008, participant)
- ENCITE (2008, participant)
- BBMRI (2008, participant)
- CONTAMED (2008, participant)
- NUTRIMENTHE (2008, participant)
- PILGRIM (2009, participant)
- CALBC (2009, participant)
- TINN (2008, participant)
- EURODRG (2009, participant)
- SPIDIA (2008, participant)
- SONODRUGS (2008, participant)
- NEUROSIS (2009, participant)
- PERSIST (2009, participant)
- EU-PACT (2008, participant)
- NEOOPIOID (2008, participant)
- DYNANETS (2009, participant)
- CHAIN (2009, participant)
- NEMO (2009, participant)
- C7 (2009, participant)
- ADAMS (2009, participant)
- DAMAGE (2010, hostInstitution)
- DAMAGE (2010, hostInstitution)
- ATTRACT (2009, participant)
- TRUST (2010, participant)
- CEREBNET (2010, participant)
- CHICOS (2010, participant)
- RICHE (2010, participant)
- DOREMI (2010, participant)
- SYBOSS (2010, participant)
- FLUPLAN (2010, hostInstitution)
- FLUPLAN (2010, hostInstitution)
- BASIS (2010, participant)
- BEST (2010, participant)
- GAMBA (2010, participant)
- HEALTH-TIES (2010, participant)
- FLUPIG (2010, participant)
- GEOCODE (2010, participant)
- SILVER (2010, participant)
- CELL-PID (2010, participant)
- TINN2 (2011, participant)
- PHARMACHILD (2011, participant)
- HEALTHCYCLE (2011, beneficiary)
- MEDIA (2011, participant)
- SHARE_M4 (2011, participant)
- EURO-BIOIMAGING (2010, participant)
- INBIOMEDvision (2011, participant)
- GRIP (2011, participant)
- ENS@T-CANCER (2011, participant)
- EUROCANPLATFORM (2011, participant)
- ENCCA (2011, participant)
- ACTIVATION OF XCI (2011, hostInstitution)
- ACTIVATION OF XCI (2011, hostInstitution)
- BLUEPRINT (2011, participant)